Krystal biotech, inc. (KRYS)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Dec'16
Assets
Current assets
Cash and cash equivalents

180,225

187,514

194,806

186,587

98,013

103,670

46,667

41,813

47,228

49,591

52,570

1,923

Short-term investments

6,479

6,171

-

-

-

8,091

-

-

-

-

-

-

Short-term investments

-

-

8,402

8,879

8,617

-

5,627

3,637

-

-

-

-

Prepaid expenses and other current assets

1,625

2,195

1,227

737

1,264

889

527

260

441

323

-

-

Prepaid assets

-

-

-

-

-

-

-

-

-

-

48

246

Total current assets

188,329

195,880

204,435

196,203

107,894

112,650

52,821

45,710

47,669

49,914

52,618

2,169

Property and equipment, net

10,264

8,475

6,863

5,961

4,354

3,014

1,632

256

182

200

55

13

Long-term investments

-

497

-

-

-

-

-

-

-

-

-

-

Prepaid rent

2,400

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset

2,633

2,709

2,796

2,906

3,001

-

-

-

-

-

-

-

Other non-current assets

1,505

1,462

138

86

455

452

-

64

-

-

-

-

Total assets

205,131

209,023

214,232

205,156

115,704

116,116

54,453

46,030

47,851

50,114

52,673

2,182

Current liabilities
Accounts payable

636

724

1,252

896

1,126

888

378

214

89

193

550

42

Current portion of lease liability

509

480

462

438

418

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

2,916

2,123

2,012

2,606

1,698

1,708

1,538

545

363

447

1,925

1

Total current liabilities

4,061

3,327

3,726

3,940

3,242

2,596

1,916

759

452

640

2,475

43

Lease liability

2,701

2,782

2,860

2,926

2,976

-

-

-

-

-

-

-

Other noncurrent liabilities

-

-

-

-

-

294

245

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

7

Related party convertible promissory notes

-

-

-

-

-

-

-

-

-

-

0

698

Convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

1,145

Total liabilities

6,762

6,109

6,586

6,866

6,218

2,890

2,161

759

452

640

2,475

1,893

Commitments and contingencies (Note 6)

-

-

-

-

-

-

0

0

0

0

0

0

Stockholders' equity
Preferred stock; $0.00001 par value; 20,000,000 shares authorized at March 31, 2020 (unaudited) and December 31, 2019; 2,061,773 shares issued, and no shares outstanding at March 31, 2020 (unaudited) and December 31, 2019

0

0

0

0

0

0

-

-

-

-

-

-

Preferred stock

-

-

-

-

-

-

0

0

0

0

0

0

Convertible preferred stock

-

-

-

-

-

-

0

0

0

0

0

0

Common stock; $0.00001 par value; 80,000,000 shares authorized at March 31, 2020 (unaudited) and December 31, 2019; 17,370,564 and 17,354,310 shares issued and outstanding at March 31, 2020 (unaudited) and December 31, 2019, respectively

0

0

0

0

0

0

0

0

0

0

0

0

Common units; no par value; no common units authorized, issued, or outstanding at December 31, 2017; 3,490,884 units authorized, issued, and outstanding at December 31, 2016

-

-

-

-

-

-

-

-

-

-

0

0

Preferred units; no par value; no preferred units authorized, issued, or outstanding at December 31, 2017; 179,613 units authorized, issued, and outstanding at December 31, 2016 (aggregate liquidation preference of $1,406)

-

-

-

-

-

-

-

-

-

-

0

1,406

Additional paid-in capital

242,733

241,951

241,325

227,690

133,540

133,183

68,542

58,769

58,619

58,544

57,875

33

Accumulated other comprehensive income

24

10

11

18

16

2

1

-2

-

-

-

-

Accumulated deficit

-44,388

-39,047

-33,690

-29,418

-24,070

-19,959

-16,251

-13,496

-11,220

-9,070

-7,677

-1,150

Total stockholders' equity

198,369

202,914

207,646

198,290

109,486

113,226

52,292

45,271

47,399

49,474

50,198

289

Total liabilities and stockholders' equity

205,131

209,023

214,232

205,156

115,704

116,116

54,453

46,030

47,851

50,114

52,673

2,182